{"entity":{"id":"paper-augment-lenalidomide-rituximab-leonard-jco-2019","kind":"paper","name":"AUGMENT: lenalidomide plus rituximab versus rituximab alone in relapsed indolent lymphoma","aka":[],"tldr":"Adding lenalidomide to rituximab more than doubled the time to progression in relapsed follicular and marginal zone lymphoma compared with rituximab alone, establishing a chemotherapy-free option for relapsed indolent lymphoma.","summary":"Phase 3 trial of 358 patients with relapsed or refractory follicular (grade 1 to 3a) or marginal zone lymphoma randomised to lenalidomide plus rituximab (R2) or placebo plus rituximab for 12 cycles.\n\nMedian progression-free survival was 39.4 versus 14.1 months (hazard ratio 0.46) and response 78 versus 53 percent; the benefit was clear in follicular lymphoma while the marginal zone subgroup was small and inconclusive. Neutropenia was more frequent with lenalidomide.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2019","url":"https://doi.org/10.1200/JCO.19.00010"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/30897038/"}],"tags":[],"related":[],"cancers":["marginal-zone-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["lenalidomide","rituximab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["augment"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/JCO.19.00010","pmid":"30897038","authors":"Leonard JP, Trneny M, Izutsu K, et al.","paperType":"rct","findings":["Median progression-free survival 39.4 vs 14.1 months; hazard ratio 0.46.","Objective response 78 percent vs 53 percent."],"whatItMeans":"Lenalidomide-rituximab is approved for relapsed follicular and marginal zone lymphoma and is a standard chemotherapy-free choice, though marginal zone-specific evidence is thinner.","caveats":["Only 63 patients had marginal zone lymphoma, with no clear progression-free survival benefit in that subgroup."],"changedPractice":true,"participants":358},"route":"/key-papers/paper-augment-lenalidomide-rituximab-leonard-jco-2019/","neighbours":{"cancer":[{"id":"marginal-zone-lymphoma","kind":"cancer","name":"Marginal zone lymphoma","route":"/cancers/marginal-zone-lymphoma/"}],"drug":[{"id":"lenalidomide","kind":"drug","name":"Lenalidomide","route":"/drugs/lenalidomide/"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/"}],"trial":[{"id":"augment","kind":"trial","name":"AUGMENT","route":"/trials/augment/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}